{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:39:56Z","timestamp":1790991596464,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UG1CA189823"],"award-info":[{"award-number":["UG1CA189823"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UG1CA233160"],"award-info":[{"award-number":["UG1CA233160"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UG1CA233196"],"award-info":[{"award-number":["UG1CA233196"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UG1CA233339"],"award-info":[{"award-number":["UG1CA233339"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UG1CA232760"],"award-info":[{"award-number":["UG1CA232760"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s00520-020-05543-5","type":"journal-article","created":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T22:02:18Z","timestamp":1591308138000},"page":"833-840","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724)"],"prefix":"10.1007","volume":"29","author":[{"given":"Costantine","family":"Albany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Dockter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Le-Rademacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Wagner-Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Einhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline M.","family":"Lafky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre","family":"Pachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Staff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Loprinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,4]]},"reference":[{"key":"5543_CR1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","volume":"32","author":"DL Hershman","year":"2014","unstructured":"Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:1941\u20131967","journal-title":"J Clin Oncol"},{"key":"5543_CR2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/PPO.0b013e31815a999b","volume":"13","author":"CL Loprinzi","year":"2007","unstructured":"Loprinzi CL, Maddocks-Christianson K, Wolf SL, Rao RD, Dyck PJB, Mantyh P, Dyck PJ (2007) The paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. Cancer J 13:399\u2013403","journal-title":"Cancer J"},{"key":"5543_CR3","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1200\/JCO.2010.33.0308","volume":"29","author":"CL Loprinzi","year":"2011","unstructured":"Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, le-Lindqwister NA, Soori GS, Jaslowski AJ, Novotny PJ, Lachance DH (2011) Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 29:1472\u20131478","journal-title":"J Clin Oncol"},{"key":"5543_CR4","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1200\/jco.2014.32.15_suppl.3595","volume":"32","author":"DR Pachman","year":"2014","unstructured":"Pachman DR, Qin R, Seisler D et al (2014) Clinical course of patients with oxaliplin-associated neuropathy: N08CB (Alliance). J Clin Oncol 32:3595","journal-title":"J Clin Oncol"},{"key":"5543_CR5","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00520-011-1141-9","volume":"20","author":"SL Wolf","year":"2012","unstructured":"Wolf SL, Barton DL, Qin R, Wos EJ, Sloan JA, Liu H, Aaronson NK, Satele DV, Mattar BI, Green NB, Loprinzi CL (2012) The relationship between numbness, tingling, and shooting\/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer 20:625\u2013632","journal-title":"Support Care Cancer"},{"key":"5543_CR6","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.1002\/cncr.27489","volume":"118","author":"BN Reeves","year":"2012","unstructured":"Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, le-Lindqwister NA, Soori GS, Jaslowski AJ, Kelaghan J, Novotny PJ, Lachance DH, Loprinzi CL (2012) Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer 118:5171\u20135178","journal-title":"Cancer"},{"key":"5543_CR7","doi-asserted-by":"publisher","first-page":"5059","DOI":"10.1007\/s00520-016-3373-1","volume":"24","author":"DR Pachman","year":"2016","unstructured":"Pachman DR, Qin R, Seisler D, Smith EML, Kaggal S, Novotny P, Ruddy KJ, Lafky JM, Ta LE, Beutler AS, Wagner-Johnston ND, Staff NP, Grothey A, Dougherty PM, Cavaletti G, Loprinzi CL (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059\u20135068","journal-title":"Support Care Cancer"},{"key":"5543_CR8","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1007\/s11136-013-0379-8","volume":"22","author":"EM Lavoie Smith","year":"2013","unstructured":"Lavoie Smith EM, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL (2013) Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 questionnaire. Qual Life Res 22:2787\u20132799","journal-title":"Qual Life Res"},{"key":"5543_CR9","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","volume":"41","author":"TJ Postma","year":"2005","unstructured":"Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, Hoang-Xuan K, Lant\u00e9ri-Minet M, Grant R, Huddart R, Moynihan C, Maher J, Lucey R (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41:1135\u20131139","journal-title":"Eur J Cancer"},{"key":"5543_CR10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1212\/WNL.0000000000006083","volume":"91","author":"JS Gewandter","year":"2018","unstructured":"Gewandter JS, Brell J, Cavaletti G, Dougherty PM, Evans S, Howie L, McDermott MP, O\u2019Mara A, Smith AG, Dastros-Pitei D, Gauthier LR, Haroutounian S, Jarpe M, Katz NP, Loprinzi C, Richardson P, Lavoie-Smith EM, Wen PY, Turk DC, Dworkin RH, Freeman R (2018) Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations. Neurology 91:403\u2013413","journal-title":"Neurology"},{"key":"5543_CR11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/BF00694340","volume":"25","author":"SM Grunberg","year":"1989","unstructured":"Grunberg SM, Sonka S, Stevenson LL, Muggia FM (1989) Progressive paresthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother Pharmacol 25:62\u201364","journal-title":"Cancer Chemother Pharmacol"},{"key":"5543_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/BF00839140","volume":"239","author":"M LoMonaco","year":"1992","unstructured":"LoMonaco M, Milone M, Batocchi AP, Padua L, Restuccia D, Tonali P (1992) Cisplatin neuropathy: clinical course and neurophysiological findings. J Neurol 239:199\u2013204","journal-title":"J Neurol"},{"key":"5543_CR13","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.nbd.2010.11.017","volume":"41","author":"JL Podratz","year":"2011","unstructured":"Podratz JL, Knight AM, Ta LE, Staff NP, Gass JM, Genelin K, Schlattau A, Lathroum L, Windebank AJ (2011) Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol Dis 41:661\u2013668","journal-title":"Neurobiol Dis"},{"key":"5543_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/PL00007853","volume":"249","author":"S Quasthoff","year":"2002","unstructured":"Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249:9\u201317","journal-title":"J Neurol"},{"key":"5543_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/01.cad.0000185185.64980.70","volume":"17","author":"J Choi","year":"2006","unstructured":"Choi J, Kong K, Mozaffar T, Holcombe RF (2006) Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer. Anti-Cancer Drugs 17:103\u2013105","journal-title":"Anti-Cancer Drugs"},{"key":"5543_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/mus.10559","volume":"29","author":"TJ Lehky","year":"2004","unstructured":"Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK (2004) Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29:387\u2013392","journal-title":"Muscle Nerve"},{"key":"5543_CR17","doi-asserted-by":"publisher","first-page":"5614","DOI":"10.1002\/cncr.27593","volume":"118","author":"KM Kidwell","year":"2012","unstructured":"Kidwell KM, Yothers G, Ganz PA, Land SR, Ko CY, Cecchini RS, Kopec JA, Wolmark N (2012) Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. Cancer 118:5614\u20135622","journal-title":"Cancer"},{"key":"5543_CR18","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1200\/JCO.2013.49.1514","volume":"31","author":"F Mols","year":"2013","unstructured":"Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV (2013) Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 31:2699\u20132707","journal-title":"J Clin Oncol"},{"key":"5543_CR19","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1200\/JCO.2006.08.6652","volume":"25","author":"SR Land","year":"2007","unstructured":"Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, Murphy K, Kuebler JP, Seay TE, Needles BM, Bearden JD III, Colman LK, Lanier KS, Pajon ER Jr, Cella D, Smith RE, O\u2019Connell MJ, Costantino JP, Wolmark N (2007) Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 25:2205\u20132211","journal-title":"J Clin Oncol"},{"key":"5543_CR20","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1188\/11.CJON.182-188","volume":"15","author":"C Tofthagen","year":"2011","unstructured":"Tofthagen C, McAllister RD, McMillan SC (2011) Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin. Clin J Oncol Nurs 15:182\u2013188","journal-title":"Clin J Oncol Nurs"},{"key":"5543_CR21","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1200\/JCO.2013.52.0536","volume":"32","author":"CL Loprinzi","year":"2014","unstructured":"Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, Seisler D, Qamar R, Lewis GC, Grothey A (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB\/Alliance). J Clin Oncol 32:997\u20131005","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s00520-021-06523-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T00:00:00Z","timestamp":1630713600000}}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05543-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-020-05543-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05543-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T05:06:06Z","timestamp":1630731966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-020-05543-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,4]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["5543"],"URL":"https:\/\/doi.org\/10.1007\/s00520-020-05543-5","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00520-021-06523-z","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,4]]},"assertion":[{"value":"28 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00520-021-06523-z","URL":"https:\/\/doi.org\/10.1007\/s00520-021-06523-z","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Einhorn owns Amgen and Biogenidec stock; Dr. Loprinzi reports personal fees from PledPharma, personal fees from Disarm Therapeutics, personal fees from Asahi Kasei, personal fees from Metys Pharmaceuticals, personal fees from OnQuality, personal fees from NKMax, and personal fees from Mitsubishi Tanabe, outside the submitted work; Dr. Wagner-Johnston reports personal fees from Regeneron, ADC Therapeutics, CALIB-R, Verastem, outside the submitted work; None of the other authors noted any potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}